Open AccessComparison of 3 Protocols for Treatment after Induction of Remission in Dogs with Lymphoma
Author(s) -
Rassnick Kenneth M.,
McEntee Margaret C.,
Erb Hollis N.,
Burke Blaise P.,
Balkman Cheryl E.,
Flory Andrea B.,
Kiselow Michael A.,
Autio Karoliina,
Gieger Tracy L.
Publication year - 2007
Publication title -
journal of veterinary internal medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.356
H-Index - 103
eISSN - 1939-1676
pISSN - 0891-6640
DOI - 10.1111/j.1939-1676.2007.tb01960.x
Subject(s) - lomustine , medicine , vincristine , procarbazine , prednisone , chop , cyclophosphamide , surgery , induction chemotherapy , chemotherapy , gastroenterology
Background : The optimal treatment after inducing complete remission (CR) in dogs with lymphoma has not been established. Hypothesis : After inducing CR with L‐asparaginase, vincristine, cyclophosphamide, doxorubicin, prednisone (L‐CHOP); consolidation with either half‐body radiation therapy (HBRT); or lomustine (CCNU) and mechlorethamine, vincristine, procarbazine, prednisone (MOPP) would improve first remission duration compared with continuing a CHOP‐based protocol for an additional 4 months. Animals : Dogs with stage III‐V lymphoma. Methods : Prospective clinical trial in which dogs initially were treated with an 8‐week induction protocol that consisted of L‐CHOP. Dogs in CR after induction were then allocated to 1 of 2 consolidation arms. A chemotherapy consolidation arm consisted of 2 treatments with CCNU and 1 cycle of MOPP. A HBRT arm consisted of 2 sequential 8.0‐Gy fractions to the cranial and caudal half‐body separated by 30 days. Vincristine was given between fractions. Results of the consolidation arms also were compared with a historical group treated with the same 8‐week induction protocol followed by CHOP therapy until week 24. Results : Overall, 67% of the dogs were in CR after 8 weeks of induction chemotherapy and were compared. Fifty‐two dogs were in the historical arm, 23 in the CCNU/MOPP arm, and 27 in the HBRT arm. No difference in first remission duration was found among groups. Median first remission duration for the historical, CCNU/MOPP, and HBRT arms were 307, 274, and 209 days, respectively ( P = .28). Overall second CR rate was 82% and was not different among groups (all P > .58). Overall remission duration ( P = .28) and survival time ( P = .48) were not different among groups. Conclusions and Clinical Importance : Consolidation with either CCNU/MOPP or HBRT showed no advantage over a standard CHOP‐based protocol.